This shows that neutralizing titers were superior with the bivalent vaccine compared to the original vaccine. And that there was an immunological response to XBB.1 with the bivalent vaccine.
This is similar to the preponderance of the other immunological data suggesting that the bivalent vaccines broaden the immune response to the variants and are superior to the original monovalent vaccine.
XBB is currently the dominant variant in the US.